Table 1 Baseline characteristics and demographics in the safety analysis set
Nifedipine CR 40 mg b.i.d. (N=177) | Nifedipine CR 40 mg q.d. (N=175) | Total (N=352) | |
|---|---|---|---|
Age, years | |||
Mean±s.d. | 55.3±10.2 | 54.2±10.1 | 54.7±10.1 |
Range | 33–85 | 29–82 | 29–85 |
Age group, n (%) | |||
<65 years | 143 (80.8) | 150 (85.7) | 293 (83.2) |
⩾65 years | 34 (19.2) | 25 (14.3) | 59 (16.8) |
Sex, n (%) | |||
Male | 125 (70.6) | 137 (78.3) | 262 (74.4) |
Female | 52 (29.4) | 38 (21.7) | 90 (25.6) |
Bodyweight, kg | |||
Mean±s.d. | 70.3±12.6 | 72.6±15.1 | 71.5±14.0 |
Range | 42.0–120.4 | 41.6–133.9 | 41.6–133.9 |
Body mass index, kg m −2 | |||
Mean±s.d. | 25.8±3.5 | 26.2±4.3 | 26.0±3.9 |
Range | 17.9–36.9 | 14.1–50.1 | 14.1–50.1 |
Duration of hypertension, years | |||
Mean±s.d. | 7.7±7.5 | 6.6±6.1 | 7.1±6.9 |
Range | 0.1–43.2 | 0.1–30.2 | 0.1–43.2 |
DBP, mm Hg | |||
Mean±s.d. | 95.3±6.1 | 95.6±6.2 | 95.5±6.1 |
Range | 83–109 | 85–109 | 83–109 |
SBP, mm Hg | |||
Mean±s.d. | 148.7±11.4 | 146.4±11.7 | 147.5±11.6 |
Range | 125–178 | 117–178 | 117–178 |
Pulse rate (beats min−1)a | |||
Mean±s.d. | 75.8±9.6 | 75.7±10.8 | |
Range | 53–98 | 52–117 | |
Comorbid conditions, n (%) | |||
DM | 20 (11.3) | 16 (9.1) | 36 (10.2) |
CKD | 8 (4.5) | 4 (2.3) | 12 (3.4) |
pMI | 1 (0.6) | 1 (0.6) | 2 (0.6) |
Previous hypertension therapy, n (%) | |||
Calcium-channel blockers | 149 (84.2) | 148 (84.6) | 297 (84.4) |
RAS agents | 70 (39.5) | 62 (35.4) | 132 (37.5) |
β-blockers | 6 (3.4) | 5 (2.9) | 11 (3.1) |
Antihypertensives | 5 (2.8) | 1 (0.6) | 6 (1.7) |
Diuretics | 3 (1.7) | 3 (1.7) | 6 (1.7) |
Serum lipid reducing agents | 2 (1.1) | 3 (1.7) | 5 (1.4) |
Urologicals | 4 (2.3) | 1 (0.6) | 5 (1.4) |
Smoking status, n (%) | |||
Non-smoker | 83 (46.9) | 75 (42.9) | 158 (44.9) |
Previous or present smoker | 94 (53.1) | 100 (57.1) | 194 (55.1) |
